CHC Healthcare Group
CHC Healthcare Group, together with its subsidiaries, trades in medical equipment, pharmaceutical products, and health food in Taiwan, China, and internationally. The company is also involved in the leasing, installing, servicing, and repairing of medical instruments for use in various specialties, such as radiation oncology, medical imaging, neurology, surgery, ophthalmology, robot rehabilitatio… Read more
CHC Healthcare Group (4164) - Net Assets
Latest net assets as of September 2025: NT$7.98 Billion TWD
Based on the latest financial reports, CHC Healthcare Group (4164) has net assets worth NT$7.98 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$14.83 Billion) and total liabilities (NT$6.86 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$7.98 Billion |
| % of Total Assets | 53.79% |
| Annual Growth Rate | 15.18% |
| 5-Year Change | 11.75% |
| 10-Year Change | 20.46% |
| Growth Volatility | 39.9 |
CHC Healthcare Group - Net Assets Trend (2009–2024)
This chart illustrates how CHC Healthcare Group's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CHC Healthcare Group (2009–2024)
The table below shows the annual net assets of CHC Healthcare Group from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$6.70 Billion | -1.04% |
| 2023-12-31 | NT$6.78 Billion | +5.82% |
| 2022-12-31 | NT$6.40 Billion | +1.41% |
| 2021-12-31 | NT$6.31 Billion | +5.23% |
| 2020-12-31 | NT$6.00 Billion | +12.84% |
| 2019-12-31 | NT$5.32 Billion | +3.58% |
| 2018-12-31 | NT$5.13 Billion | +4.46% |
| 2017-12-31 | NT$4.91 Billion | -1.11% |
| 2016-12-31 | NT$4.97 Billion | -10.72% |
| 2015-12-31 | NT$5.57 Billion | +18.67% |
| 2014-12-31 | NT$4.69 Billion | +0.59% |
| 2013-12-31 | NT$4.66 Billion | +21.62% |
| 2012-12-31 | NT$3.83 Billion | +32.41% |
| 2011-12-31 | NT$2.90 Billion | +37.79% |
| 2010-12-31 | NT$2.10 Billion | +160.96% |
| 2009-12-31 | NT$805.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CHC Healthcare Group's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6916.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$441.94 Million | 7.01% |
| Common Stock | NT$1.67 Billion | 26.47% |
| Other Comprehensive Income | NT$516.87 Million | 8.20% |
| Other Components | NT$3.68 Billion | 58.32% |
| Total Equity | NT$6.30 Billion | 100.00% |
CHC Healthcare Group Competitors by Market Cap
The table below lists competitors of CHC Healthcare Group ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
i-SENS Inc
KQ:099190
|
$125.86 Million |
|
Daqing Huake Co Ltd
SHE:000985
|
$125.91 Million |
|
China Aircraft Leasing Group Holdings Limited
PINK:CFRLF
|
$125.92 Million |
|
Equity Commonwealth
NYSE:EQC
|
$125.93 Million |
|
91App Inc
TWO:6741
|
$125.83 Million |
|
CAC Holdings Corporation
F:CB4
|
$125.82 Million |
|
Salmon Evolution Holding AS
OL:SALME
|
$125.75 Million |
|
Copperbank Resources Corp
OTCQX:CPPKF
|
$125.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHC Healthcare Group's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,458,415,000 to 6,303,271,000, a change of -155,144,000 (-2.4%).
- Net income of 168,384,000 contributed positively to equity growth.
- Dividend payments of 349,055,000 reduced retained earnings.
- New share issuances of 776,000 increased equity.
- Other comprehensive income increased equity by 29,993,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$168.38 Million | +2.67% |
| Dividends Paid | NT$349.06 Million | -5.54% |
| Share Issuances | NT$776.00K | +0.01% |
| Other Comprehensive Income | NT$29.99 Million | +0.48% |
| Other Changes | NT$-5.24 Million | -0.08% |
| Total Change | NT$- | -2.40% |
Book Value vs Market Value Analysis
This analysis compares CHC Healthcare Group's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.16x to 0.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$7.48 | NT$31.10 | x |
| 2010-12-31 | NT$21.30 | NT$31.10 | x |
| 2011-12-31 | NT$26.59 | NT$31.10 | x |
| 2012-12-31 | NT$34.31 | NT$31.10 | x |
| 2013-12-31 | NT$35.90 | NT$31.10 | x |
| 2014-12-31 | NT$35.77 | NT$31.10 | x |
| 2015-12-31 | NT$34.83 | NT$31.10 | x |
| 2016-12-31 | NT$35.47 | NT$31.10 | x |
| 2017-12-31 | NT$35.13 | NT$31.10 | x |
| 2018-12-31 | NT$28.52 | NT$31.10 | x |
| 2019-12-31 | NT$30.39 | NT$31.10 | x |
| 2020-12-31 | NT$29.03 | NT$31.10 | x |
| 2021-12-31 | NT$32.77 | NT$31.10 | x |
| 2022-12-31 | NT$32.02 | NT$31.10 | x |
| 2023-12-31 | NT$33.36 | NT$31.10 | x |
| 2024-12-31 | NT$32.38 | NT$31.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CHC Healthcare Group utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.68%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 2.26x
- Recent ROE (2.67%) is below the historical average (7.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.86% | 3.70% | 0.06x | 3.76x | NT$-66.86 Million |
| 2010 | 23.20% | 25.89% | 0.48x | 1.86x | NT$275.11 Million |
| 2011 | 20.28% | 29.24% | 0.37x | 1.89x | NT$295.82 Million |
| 2012 | 11.26% | 21.65% | 0.30x | 1.75x | NT$48.36 Million |
| 2013 | 6.37% | 14.39% | 0.30x | 1.48x | NT$-168.87 Million |
| 2014 | 5.67% | 12.71% | 0.27x | 1.62x | NT$-202.91 Million |
| 2015 | 4.39% | 9.46% | 0.24x | 1.92x | NT$-289.61 Million |
| 2016 | 3.20% | 7.21% | 0.23x | 1.97x | NT$-337.81 Million |
| 2017 | -1.76% | -4.09% | 0.20x | 2.16x | NT$-578.03 Million |
| 2018 | 6.50% | 12.90% | 0.23x | 2.18x | NT$-173.81 Million |
| 2019 | 7.66% | 13.40% | 0.26x | 2.17x | NT$-121.04 Million |
| 2020 | 6.27% | 14.34% | 0.22x | 1.97x | NT$-218.35 Million |
| 2021 | 6.27% | 15.64% | 0.19x | 2.07x | NT$-226.82 Million |
| 2022 | 5.81% | 11.99% | 0.23x | 2.09x | NT$-257.59 Million |
| 2023 | 6.49% | 10.80% | 0.28x | 2.11x | NT$-226.98 Million |
| 2024 | 2.67% | 4.68% | 0.25x | 2.26x | NT$-461.94 Million |
Industry Comparison
This section compares CHC Healthcare Group's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $6,172,182,000
- Average return on equity (ROE) among peers: 6.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHC Healthcare Group (4164) | NT$7.98 Billion | 0.86% | 0.86x | $125.84 Million |
| Excelsior Medical Co Ltd (4104) | $10.30 Billion | 6.48% | 0.60x | $236.51 Million |
| ShareHope Medicine Co Ltd (8403) | $2.05 Billion | 6.08% | 0.64x | $63.98 Million |